PharmaCyte Biotech Inc (PMCB)

[$Pistol Pete$]

$PMCB Value Composite Update on PharmaCyte Biotech, Inc. (OTCPK:PMCB)



The Value Composite One (VC1) is a method that investors use to determine a company’s value. The Value Composite score of PharmaCyte Biotech, Inc. (OTCPK:PMCB) is 75. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of PharmaCyte Biotech, Inc. (OTCPK:PMCB) is 78.

Technicals at a Glance
In taking a look at some other notable technicals, PharmaCyte Biotech, Inc. (OTCPK:PMCB)’s ROIC is -2.429276. The ROIC 5 year average is -1.759976 and the ROIC Quality ratio is 0.520433. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a firm is at turning capital into profits.

Shareholder Yield
We also note that PharmaCyte Biotech, Inc. (OTCPK:PMCB) has a Shareholder Yield of -0.141878 and a Shareholder Yield (Mebane Faber) of -0.10079. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

PharmaCyte Biotech, Inc. (OTCPK:PMCB) has a current MF Rank of 14033. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

Price Index
We can now take aquick look at some historical stock price index data. PharmaCyte Biotech, Inc. (OTCPK:PMCB) presently has a 10 month price index of 1.49213. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 1.56842, the 24 month is 1.01017, and the 36 month is 0.27169. Narrowing in a bit closer, the 5 month price index is 2.85753, the 3 month is 0.81484, and the 1 month is currently 0.92711.